

# Head and Neck Disease-Oriented Team

---

## Clinical Research Treatment Trial Flowchart

**Clinical Research Manager:**  
Mehir Tharani

**Clinical Research Coordinators:**  
Bao-An Huynh  
Natalie Arechiga  
Erin Palmer-Torrison  
Anastasiia Reipolska



**Neo-adjuvant or Adjuvant HNSCC**

**UCI 22-132**

De-escalated Radiation for HPV 16+ Squamous Cell Carcinoma of the Oropharynx  
 Coord: E. Palmer-Torrison  
 Accrual: 17/111

**HN009**

Cisplatin Q3 weeks vs Weekly Locally Advanced HNSCC  
 Coord: E. Palmer-Torrison  
 Accrual: 0/5

**UCI 23-190**

Observation vs IP Adjuvant  
 Coord: E. Palmer-Torrison  
 Accrual: 0/5

**UCI 21-173**

Eval of Clinical & Radiological Benefit AHCC in Combo w/ SOC Tx for HPV+ Pts w/ HNSCC  
 Coord: A. Reipolska  
 Accrual: 0/34

**1<sup>st</sup> Line Recurrent/Metastatic HNSCC**

**UCI 23-106**

Pembro + Danvatirsen vs Pembro in 1<sup>st</sup> line Recurrent/Metastatic HNSCC  
 Coord: N. Arechiga  
 Accrual: 1/5

**UCI 23-228**

TAK676 + Pembro  
 1<sup>st</sup> line Recurrent Metastatic HNSCC  
 Coord: B. Huynh  
 Accrual: 0/5

**Recurrent/Metastatic Salivary Gland Cancer**

**ETCTN 10553**

Darolutamide + Leuprolide Acetate in Hormone Naïve AR+ Salivary Gland Cancer  
 Coord: B. Huynh  
 Accrual: 1/5

**EA3202**

2<sup>nd</sup>/3<sup>rd</sup> line Chemo +Cetuximab vs Chemo+Bev vs Atezo+Bev  
 Recurrent HNSCC  
 Coord: E. Torrison-Palmer  
 Accrual: 2/5

**Alliance A092105**

2<sup>nd</sup> line Ipi/Nivo +/- Cabozantinib  
 Recurrent NPC  
 Coord: B. Huynh  
 Accrual: 0/5



## Broad Phase 1 Trials

**UCI 22-87**  
(RMC-6236)

Mechanism: TKI  
Coordinator: Oliver  
Quines  
Accrual: 18/25

**UCI 21-40**

*(Locally Advanced or Metastatic Solid Tumors)*

DF6002 as a Monotherapy  
and in Combination w/ nivo  
Valerin  
CRC: B. Huynh  
Accrual: 5/10  
**Waitlist only**

**UCI 22-221**

BiTe of B7-H6

(Central B7-H6 testing)  
HCC and Pancreatic  
(also NSCLC, HNSCC,  
CRC, and gastric)

Coord: P. Yang  
Accrual: 3/12  
**Waitlist only**

**UCI 23-148**

CJRB-01 (oral) +  
Pembrolizumab  
Mechanism: Live  
biotherapeutic product  
containing a novel strain  
belonging in the species  
*Leuconostoc*  
*mesenteroides* (*L.*  
*mesenteroides* +  
Pembrolizumab  
Coord: J. Choe  
Accrual: 0/6

**UCI 23-197**

DF6215 (IL-2)  
PI: Valerin  
CRC: N. Arechiga  
Accrual: 1/5  
**Waitlist only**